Key facts: Novartis to Acquire Avidity Biosciences for $12 Billion; Expands Pipeline
Thời gian đọc: dưới 1 phút
- Novartis will acquire Avidity Biosciences for about $12 billion, paying $72 per share, a 46% premium. The deal is set to close in early 2026, pending Avidity's program separation.12
- In 2025, Novartis acquired Tourmaline Bio for $1.4 billion and agreed to buy Regulus Therapeutics for up to $1.7 billion, enhancing its drug pipeline.3